Pliva's Interim Profits Rise 49.5%

29 September 1996

Croatian company Pliva has announced a rise of 49.5% in its pretax profits for the January-June 1996 period to 368.3 million kuna ($70.2 million). The firm's earnings per share rose from 457 kuna in the 1995 first half to 520 kuna, according to Reuters.

Zeljko Covic, Pliva's chief executive, said: "this is a significant rise, taking into account that (at the end of) June there were 60,000 more shares outstanding than in the year-ago period." He added that the results were extremely good and that all businesses had recorded output growth.

Exports rose to $102 million from $86 million at the expense of domestic sales, the percentage of which shrank from 37% to 34% of the total.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight